Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioFINDER 2 diagnostic PET study in cognitive disorders
2024-511842-38-00Phase 2Authorised
- Sponsor
- Region Skåne
- Start
- Sep 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of flutemetamol and [18F]RO-948 (2 cohorts), sponsored by Region Skåne. Planned start Sep 2024; status: authorised.
02
Drugs
flutemetamol[18F]RO-948
Beyond the preview
Go deeper on 2024-511842-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511842-38-00.